Active-ingredient Dossier
Adalimumab
Active-ingredient Dossier for Adalimumab (tumor necrosis factor inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: AMGEVITA
- Brand: HADLIMA
- Brand: HUMIRA
- Brand: HYRIMOZ
- Brand: YUFLYMA
- Brand: ADALICIP
- Therapeutic area: Immunology
What is
Adalimumab Adalimumab is a tumor necrosis factor inhibitor.
Australian brands containing
Adalimumab — AMGEVITA — HADLIMA — HUMIRA — HYRIMOZ — YUFLYMA — ADALICIP — CIPTUNEC — ABRILADA — HULIO
Therapeutic areas
Adalimumab is registered in Infectious Disease, with 9 brands containing the ingredient on the ARTG.
Sponsor landscape
Eight sponsors market adalimumab in Australia, including Cipla, Pfizer, Amgen, Samsung Bioepis AU, Maxx Pharma, and AbbVie.
PBS and regulatory activity
Five brands containing adalimumab have PBS-listed items. The latest PBS schedule date is 1 May 2026. In the 2024–25 fiscal year, PBS expenditure on adalimumab was approximately $221.2 million across 390,442 scripts. The latest PBAC outcome was recorded on 1 July 2025, with 6 brands holding PBAC outcomes on record. The latest AusPAR was published on 23 August 2022, with 4 brands holding AusPARs on record.